TY - JOUR
T1 - Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy
AU - Mian, Michael
AU - Ferreri, Andrés J M
AU - Rossi, Andrea
AU - Conconi, Annarita
AU - Tsang, Richard
AU - Gospodarowicz, Mary K.
AU - Oldani, Elena
AU - Federico, Massimo
AU - Luminari, Stefano
AU - Pogliani, Enrico M.
AU - Rossini, Fausto
AU - Cabrera, Maria E.
AU - Martelli, Maurizio
AU - Gutierrez-Garcia, Gonzalo
AU - Busetto, Mario
AU - Cavalli, Franco
AU - Zucca, Emanuele
AU - Rambaldi, Alessandro
AU - Cortelazzo, Sergio
PY - 2013/1
Y1 - 2013/1
N2 - Consolidation radiotherapy (cRT) in patients with stage I/II diffuse large B-cell lymphoma of the Waldeyer's ring (WR-DLBCL) in complete remission (CR) after induction chemotherapy (CHT) is often associated with relevant acute and chronic toxicity, and its impact on survival remains to be defined. A total of 184 patients in CR after anthracycline-based chemotherapy were retrospectively analyzed: 62 underwent CHT alone (CHT group), while 122 (66%) patients were referred to cRT (CHT + RT group). After a median follow-up of 54 months, 36 patients (20%) experienced relapse: 19% in the CHT group and 20% in the CHT + RT group. At the time of analysis 47 (76%) CHT patients and 97 (80%) CHT + RT patients were alive. Five-year overall survival (OS), disease-free survival (DFS) and lymphoma-specific survival (LSS) were 80%, 74% and 86%, respectively. Five-year OS was significantly prolonged in the CHT + RT group, while DFS and LSS were similar between groups. This discrepancy was attributed to a high percentage of deaths due to unrelated causes in CHT patients. cRT does not prolong LSS in patients with early-stage WR-DLBCL in CR after anthracycline-containing chemotherapy. An international confirmatory trial is warranted.
AB - Consolidation radiotherapy (cRT) in patients with stage I/II diffuse large B-cell lymphoma of the Waldeyer's ring (WR-DLBCL) in complete remission (CR) after induction chemotherapy (CHT) is often associated with relevant acute and chronic toxicity, and its impact on survival remains to be defined. A total of 184 patients in CR after anthracycline-based chemotherapy were retrospectively analyzed: 62 underwent CHT alone (CHT group), while 122 (66%) patients were referred to cRT (CHT + RT group). After a median follow-up of 54 months, 36 patients (20%) experienced relapse: 19% in the CHT group and 20% in the CHT + RT group. At the time of analysis 47 (76%) CHT patients and 97 (80%) CHT + RT patients were alive. Five-year overall survival (OS), disease-free survival (DFS) and lymphoma-specific survival (LSS) were 80%, 74% and 86%, respectively. Five-year OS was significantly prolonged in the CHT + RT group, while DFS and LSS were similar between groups. This discrepancy was attributed to a high percentage of deaths due to unrelated causes in CHT patients. cRT does not prolong LSS in patients with early-stage WR-DLBCL in CR after anthracycline-containing chemotherapy. An international confirmatory trial is warranted.
KW - Chemotherapy
KW - DLBCL
KW - Lymphoma
KW - Radiotherapy
KW - Waldeyer
UR - http://www.scopus.com/inward/record.url?scp=84870950629&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84870950629&partnerID=8YFLogxK
U2 - 10.3109/10428194.2012.710907
DO - 10.3109/10428194.2012.710907
M3 - Article
C2 - 22784364
AN - SCOPUS:84870950629
VL - 54
SP - 62
EP - 68
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 1
ER -